in these four patients for the above reasons. One patient had an absent superior pancreaticoduodenal artery, and so the stem cells were injected into the inferior ...
Cell Transplantation, Vol. 23, pp. 1075–1085, 2014 Printed in the USA. All rights reserved. Copyright Ó 2014 Cognizant Comm. Corp.
0963-6897/14 $90.00 + .00 DOI: http://dx.doi.org/10.3727/096368913X665576 E-ISSN 1555-3892 www.cognizantcommunication.com
Efficacy and Safety of Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Type 2 Diabetes Mellitus: A Randomized Placebo-Controlled Study Anil Bhansali,* Premkumar Asokumar,* Rama Walia,* Shobhit Bhansali,* Vivek Gupta,† Ashish Jain,‡ Naresh Sachdeva,* Rati Ram Sharma,‡ Neelam Marwaha,‡ and Niranjan Khandelwal† *Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, India †Department of Radiodiagnosis, Post Graduate Institute of Medical Education and Research, Chandigarh, India ‡Department of Transfusion Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India
There is a growing interest in cell-based therapies in T2DM as b-cell failure is progressive and inexorable with the advancing duration of disease. This prospective, randomized, single-blinded placebo-controlled study evaluates the efficacy and safety of autologous bone marrow-derived stem cell transplantation (ABMSCT) in T2DM. Twenty-one patients with triple oral antidiabetic drug failure and requiring insulin ³0.4 IU per kg per day with HbA1c